{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:19Z","timestamp":1787786179785,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nivolumab has been approved for treating \u2265\u200910 cancer types. However, there is limited information on the incidence of rare, but potentially serious, treatment-related adverse events (TRAEs), as well as notable TRAEs in patients with certain medical disorders or older patients in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed pooled analyses of data from published post-marketing surveillance in Japan of nivolumab monotherapy for patients with malignant melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, and gastric cancer to determine the frequencies of 20 categories of TRAEs of special interest overall and in patient groups with higher perceived safety risks (history of autoimmune disease, interstitial lung disease, tuberculosis, or hepatitis B\/C; patients vaccinated during nivolumab treatment; and older patients [\u2265\u200975\u00a0years]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall population comprised 7421 patients treated with nivolumab. TRAEs were reported in 49.1% of patients, with grade\u2009\u2265\u20093 TRAEs in 16.7%. Endocrine disorders (14.4%), hepatobiliary disorders (10.9%), and interstitial lung disease (7.0%) were the three most common categories (any grade). The incidences of rare TRAEs with high risk of becoming serious, which occurred in &lt;\u20091% of patients, were consistent with those in previous reports. The frequencies of TRAEs were not markedly increased in the specified patient groups relative to the overall population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To our knowledge, this is the largest study examining the safety of nivolumab-treated patients in real-world clinical practice including rare but potentially serious TRAEs. We found no new signals in the safety of nivolumab among the patient groups relative to the overall population, and no additional safety measures are required in these groups.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> UMIN000048892 (overall analysis), JapicCTI-163272 (melanoma), Japic-163271 (non-small cell lung cancer), JapicCTI-184071 (head and neck cancer), JapicCTI-184070 (gastric cancer), and JapicCTI-184069 (renal cell cancer).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-024-02515-1","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:17:31Z","timestamp":1717705051000},"page":"932-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan"],"prefix":"10.1007","volume":"29","clinical-trial-number":[{"clinical-trial-number":"umin000048892","registry":"10.18810\/umin-japan"}],"author":[{"given":"Kenji","family":"Hiraizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Midorikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunehisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-9574","authenticated-orcid":false,"given":"Takahiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2515_CR1","unstructured":"Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Opdivo\u00ae (nivolumab) intravenous infusion. Interview form. https:\/\/www.opdivo.jp\/system\/files\/2023-03\/OPD_IF_1.pdf. Accessed 29 Aug 2023. (In Japanese)"},{"key":"2515_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"2515_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"2515_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"2515_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/s0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471. https:\/\/doi.org\/10.1016\/s0140-6736(17)31827-5","journal-title":"Lancet"},{"key":"2515_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"2515_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"2515_CR8","unstructured":"Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Opdivo\u00ae (nivolumab) intravenous infusion. Pharmaceutical risk management plan. https:\/\/www.opdivo.jp\/system\/files\/2023-04\/OPD_RMP.pdf. Accessed 29 Aug 2023. (In Japanese)"},{"key":"2515_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1346-8138.16432","volume":"49","author":"H Uhara","year":"2022","unstructured":"Uhara H, Tsuchida T, Kiyohara Y et al (2022) Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: final analysis of a post-marketing surveillance. J Dermatol 49:862\u2013871. https:\/\/doi.org\/10.1111\/1346-8138.16432","journal-title":"J Dermatol"},{"key":"2515_CR10","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1111\/cas.15117","volume":"112","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto N, Nakanishi Y, Gemma A et al (2021) Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance. Cancer Sci 112:4692\u20134701. https:\/\/doi.org\/10.1111\/cas.15117","journal-title":"Cancer Sci"},{"key":"2515_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10147-022-02155-3","volume":"27","author":"H Uemura","year":"2022","unstructured":"Uemura H, Tomita Y, Nonomura N et al (2022) Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance. Int J Clin Oncol 27:1061\u20131067. https:\/\/doi.org\/10.1007\/s10147-022-02155-3","journal-title":"Int J Clin Oncol"},{"key":"2515_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10147-021-01949-1","volume":"26","author":"M Tahara","year":"2021","unstructured":"Tahara M, Kiyota N, Nibu KI et al (2021) Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. Int J Clin Oncol 26:1619\u20131627. https:\/\/doi.org\/10.1007\/s10147-021-01949-1","journal-title":"Int J Clin Oncol"},{"key":"2515_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10120-021-01244-y","volume":"25","author":"K Yamaguchi","year":"2022","unstructured":"Yamaguchi K, Boku N, Muro K et al (2022) Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric\/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study. Gastric Cancer 25:245\u2013253. https:\/\/doi.org\/10.1007\/s10120-021-01244-y. (Correction: Gastric Cancer 2022;2025(2021):2254)","journal-title":"Gastric Cancer"},{"key":"2515_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102687","volume":"19","author":"W Xie","year":"2020","unstructured":"Xie W, Huang H, Xiao S et al (2020) Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies. Autoimmun Rev 19:102687. https:\/\/doi.org\/10.1016\/j.autrev.2020.102687","journal-title":"Autoimmun Rev"},{"key":"2515_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jgh3.12737","volume":"6","author":"T Nakabori","year":"2022","unstructured":"Nakabori T, Abe Y, Higashi S et al (2022) Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. JGH Open 6:309\u2013316. https:\/\/doi.org\/10.1002\/jgh3.12737","journal-title":"JGH Open"},{"key":"2515_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000019013","volume":"99","author":"D Pu","year":"2020","unstructured":"Pu D, Yin L, Zhou Y et al (2020) Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore) 99:e19013. https:\/\/doi.org\/10.1097\/md.0000000000019013","journal-title":"Medicine (Baltimore)"},{"key":"2515_CR17","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/cam4.2868","volume":"9","author":"S Byeon","year":"2020","unstructured":"Byeon S, Cho JH, Jung HA et al (2020) PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence. Cancer Med 9:2352\u20132362. https:\/\/doi.org\/10.1002\/cam4.2868","journal-title":"Cancer Med"},{"key":"2515_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12916-021-02194-z","volume":"19","author":"S Su","year":"2021","unstructured":"Su S, Ye MF, Cai XT et al (2021) Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. BMC Med 19:322. https:\/\/doi.org\/10.1186\/s12916-021-02194-z","journal-title":"BMC Med"},{"key":"2515_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","volume":"6","author":"H L\u00e4ubli","year":"2018","unstructured":"L\u00e4ubli H, Balmelli C, Kaufmann L et al (2018) Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer 6:40. https:\/\/doi.org\/10.1186\/s40425-018-0353-7","journal-title":"J Immunother Cancer"},{"key":"2515_CR20","unstructured":"Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Opdivo\u00ae (nivolumab) intravenous infusion. Package insert. https:\/\/www.opdivo.jp\/system\/files\/2023-03\/OPD_PI.pdf. Accessed 29 Aug 2023. (In Japanese)"},{"key":"2515_CR21","unstructured":"Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K. Opdivo\u00ae (nivolumab) intravenous infusion. Proper use guide (monotherapy). https:\/\/www.opdivo.jp\/system\/files\/2023-03\/OPD_guide.pdf. Accessed 29 Aug 2023. (In Japanese)"},{"key":"2515_CR22","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P et al (2018) Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 103:3144\u20133154. https:\/\/doi.org\/10.1210\/jc.2018-00728","journal-title":"J Clin Endocrinol Metab"},{"key":"2515_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F et al (2019) A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51:145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"key":"2515_CR24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"2515_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/wnl.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/wnl.0000000000004359","journal-title":"Neurology"},{"key":"2515_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Quandt Z, Young A, Anderson M (2020) Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 200:131\u2013140. https:\/\/doi.org\/10.1111\/cei.13424","journal-title":"Clin Exp Immunol"},{"key":"2515_CR27","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D et al (2019) Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24:e327\u2013e337. https:\/\/doi.org\/10.1634\/theoncologist.2018-0618","journal-title":"Oncologist"},{"key":"2515_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21\u201329. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.008","journal-title":"Eur J Cancer"},{"key":"2515_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.038","journal-title":"Eur J Cancer"},{"key":"2515_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/rhu.0000000000001314","volume":"27","author":"E Efuni","year":"2021","unstructured":"Efuni E, Cytryn S, Boland P et al (2021) Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheumatol 27:267\u2013271. https:\/\/doi.org\/10.1097\/rhu.0000000000001314","journal-title":"J Clin Rheumatol"},{"key":"2515_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00262-021-02985-6","volume":"71","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Lampaki S, Koliou GA et al (2022) Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother 71:327\u2013337. https:\/\/doi.org\/10.1007\/s00262-021-02985-6","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003066","volume":"9","author":"BR Halle","year":"2021","unstructured":"Halle BR, Betof Warner A, Zaman FY et al (2021) Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer 9:e003066. https:\/\/doi.org\/10.1136\/jitc-2021-003066","journal-title":"J Immunother Cancer"},{"key":"2515_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/rhu.0000000000001863","volume":"28","author":"JP Higgins","year":"2022","unstructured":"Higgins JP, Trinh AV, Watson ML et al (2022) A safety analysis of programmed death 1 pathway inhibitors in patients with solid tumor malignancies and preexisting autoimmune disease. J Clin Rheumatol 28:338\u2013345. https:\/\/doi.org\/10.1097\/rhu.0000000000001863","journal-title":"J Clin Rheumatol"},{"key":"2515_CR34","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","volume":"70","author":"S Hoa","year":"2021","unstructured":"Hoa S, Laaouad L, Roberts J et al (2021) Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother 70:2197\u20132207. https:\/\/doi.org\/10.1007\/s00262-021-02851-5","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR35","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L et al (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol 71:2100\u20132111. https:\/\/doi.org\/10.1002\/art.41068","journal-title":"Arthritis Rheumatol"},{"key":"2515_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/cji.0000000000000377","volume":"44","author":"C Yeung","year":"2021","unstructured":"Yeung C, Kartolo A, Holstead R et al (2021) Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases. J Immunother 44:362\u2013370. https:\/\/doi.org\/10.1097\/cji.0000000000000377","journal-title":"J Immunother"},{"key":"2515_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934093","volume":"12","author":"Y Yu","year":"2022","unstructured":"Yu Y, Zhou Y, Zhang X et al (2022) Immune checkpoint inhibitors in the treatment of patients with cancer and preexisting psoriasis: a systematic review and meta-analysis of observational studies. Front Oncol 12:934093. https:\/\/doi.org\/10.3389\/fonc.2022.934093","journal-title":"Front Oncol"},{"key":"2515_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y et al (2020) Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 69:15\u201322. https:\/\/doi.org\/10.1007\/s00262-019-02431-8","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","volume":"155","author":"Y Tasaka","year":"2021","unstructured":"Tasaka Y, Honda T, Nishiyama N et al (2021) Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 155:120\u2013126. https:\/\/doi.org\/10.1016\/j.lungcan.2021.03.014","journal-title":"Lung Cancer"},{"key":"2515_CR40","doi-asserted-by":"publisher","first-page":"2102512","DOI":"10.1183\/13993003.02512-2021","volume":"60","author":"M Ahmed","year":"2022","unstructured":"Ahmed M, Tezera LB, Elkington PT et al (2022) The paradox of immune checkpoint inhibition re-activating tuberculosis. Eur Respir J 60:2102512. https:\/\/doi.org\/10.1183\/13993003.02512-2021","journal-title":"Eur Respir J"},{"key":"2515_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2020.05.020","volume":"146","author":"GH Chan","year":"2020","unstructured":"Chan GH, Gwee YX, Low JL et al (2020) Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or hepatitis B: experience from a single Asian centre. Lung Cancer 146:145\u2013153. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.020","journal-title":"Lung Cancer"},{"key":"2515_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002960","volume":"9","author":"S Bae","year":"2021","unstructured":"Bae S, Kim YJ, Kim MJ et al (2021) Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer 9:e002960. https:\/\/doi.org\/10.1136\/jitc-2021-002960","journal-title":"J Immunother Cancer"},{"key":"2515_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa126","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O et al (2020) Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors. Open Forum Infect Dis 7:ofaa126. https:\/\/doi.org\/10.1093\/ofid\/ofaa126","journal-title":"Open Forum Infect Dis"},{"key":"2515_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2021.05.034","volume":"158","author":"HW Kim","year":"2021","unstructured":"Kim HW, Kim JS, Lee SH (2021) Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors\u2014a nationwide population-based cohort study. Lung Cancer 158:107\u2013114. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.034","journal-title":"Lung Cancer"},{"key":"2515_CR45","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00262-021-02905-8","volume":"70","author":"GR Stroh","year":"2021","unstructured":"Stroh GR, Peikert T, Escalante P (2021) Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area. Cancer Immunol Immunother 70:3105\u20133111. https:\/\/doi.org\/10.1007\/s00262-021-02905-8","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105853","volume":"161","author":"Y Im","year":"2020","unstructured":"Im Y, Lee J, Kim SJ et al (2020) Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respir Med 161:105853. https:\/\/doi.org\/10.1016\/j.rmed.2019.105853","journal-title":"Respir Med"},{"key":"2515_CR47","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00262-021-03082-4","volume":"71","author":"Z Lin","year":"2022","unstructured":"Lin Z, Zhang X, Zhou Y et al (2022) Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer Immunol Immunother 71:1247\u20131255. https:\/\/doi.org\/10.1007\/s00262-021-03082-4","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR48","unstructured":"Japanese Society of Hepatology. Hepatitis B treatment guidelines. Appendix 3. Guidelines for measures against hepatitis B caused by immunosuppression and chemotherapy. https:\/\/www.jsh.or.jp\/lib\/files\/medical\/guidelines\/jsh_guidlines\/B_document-3_v2.pdf. Accessed 4 Aug 2023. (In Japanese)"},{"key":"2515_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/ciz202","volume":"70","author":"CR Chong","year":"2020","unstructured":"Chong CR, Park VJ, Cohen B et al (2020) Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 70:193\u2013199. https:\/\/doi.org\/10.1093\/cid\/ciz202","journal-title":"Clin Infect Dis"},{"key":"2515_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3892\/ol.2020.11875","volume":"20","author":"T Sakakida","year":"2020","unstructured":"Sakakida T, Ishikawa T, Uchino J et al (2020) Safety and tolerability of PD-1\/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. Oncol Lett 20:14. https:\/\/doi.org\/10.3892\/ol.2020.11875","journal-title":"Oncol Lett"},{"key":"2515_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.08.030","volume":"157","author":"K Saleh","year":"2021","unstructured":"Saleh K, Auperin A, Martin N et al (2021) Efficacy and safety of immune checkpoint inhibitors in elderly patients (\u226570 years) with squamous cell carcinoma of the head and neck. Eur J Cancer 157:190\u2013197. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.030","journal-title":"Eur J Cancer"},{"key":"2515_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000871","volume":"8","author":"A Samani","year":"2020","unstructured":"Samani A, Zhang S, Spiers L et al (2020) Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer 8:e000871. https:\/\/doi.org\/10.1136\/jitc-2020-000871","journal-title":"J Immunother Cancer"},{"key":"2515_CR53","doi-asserted-by":"publisher","first-page":"10010","DOI":"10.1200\/JCO.2016.34.15_suppl.10010","volume":"34","author":"H Singh","year":"2016","unstructured":"Singh H, Kim G, Maher VE et al (2016) FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol 34:10010. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.10010","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02515-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:08:17Z","timestamp":1719223697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02515-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02515-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenji Hiraizumi, Chikara Honda, Ayu Watanabe, Takafumi Nakao, and Takahiko Sakamoto are employees of Ono Pharmaceutical Co., Ltd. Shuichi Midorikawa, Hiromi Abe, Nobuki Matsui, and Tsunehisa Yamamoto are employees of Bristol-Myers Squibb K.K. and hold stock or stock options in Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As explained in the original reports [\u2013], each PMS conformed to the Japanese Good Post-Marketing Study Practice (GPSP) regulations. Each participating hospital agreed to contracts for each surveillance with the study sponsor. No intervention was made for the purpose of this study; therefore, no written informed consent was required from each patient. The publication of the original PMS and the use of the information in this study were carried out within the Japanese GPSP regulations. Data were used from the participating institutions that consented to data posting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}